Real-World Study of Enzalutamide and Abiraterone Acetate (With Prednisone) Tolerability (REAAcT)
A Multicenter, Two-arm, Prospective, Observational Study to Characterize the Tolerability of Treatment With Enzalutamide or Abiraterone Acetate (With Prednisone) for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Alabama
-
Homewood, Alabama, United States
-
-
California
-
La Mesa, California, United States
-
-
Colorado
-
Wheat Ridge, Colorado, United States
-
-
Florida
-
Daytona Beach, Florida, United States
-
-
Indiana
-
Indianapolis, Indiana, United States
-
Jeffersonville, Indiana, United States
-
-
Michigan
-
Saint Clair Shores, Michigan, United States
-
-
New Jersey
-
Englewood, New Jersey, United States
-
Lawrenceville, New Jersey, United States
-
Morristown, New Jersey, United States
-
-
New York
-
Poughkeepsie, New York, United States
-
Syracuse, New York, United States
-
-
Ohio
-
Middleburg Heights, Ohio, United States
-
-
Oregon
-
Springfield, Oregon, United States
-
-
Pennsylvania
-
Bala-Cynwyd, Pennsylvania, United States
-
Lancaster, Pennsylvania, United States
-
-
South Carolina
-
Charleston, South Carolina, United States
-
Myrtle Beach, South Carolina, United States
-
-
Texas
-
San Antonio, Texas, United States
-
-
Virginia
-
Virginia Beach, Virginia, United States
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Male 18 years of age or older
- Have confirmed metastatic adenocarcinoma of the prostate
- Are starting treatment with enzalutamide or abiraterone acetate (with prednisone) for metastatic castration-resistant prostate cancer (mCRPC) at the full recommended dose per each drug's respective prescribing information (PI)
- Have an Eastern Cooperative Oncology Group Performance Status score of 0 or 1
- Sign written informed consent
Exclusion Criteria:
- Have a pre-existing central nervous system (CNS) condition (including, but not limited to, history of stroke or dementia) that, in the participating physician's judgment, would preclude participation in the study
- Have known mental illness including, but not limited to, major depressive disorder, general anxiety disorder, or bipolar disorder that, in the participating physician's opinion, could significantly confound the patient-reported outcome (PRO) assessments
- Have a history of or ongoing seizure disorder
- Have severe hepatic impairment (Child-Pugh Class C)
- Have an active infection (example, human immunodeficiency virus [HIV], viral hepatitis) or other medical condition that would contraindicate the use of prednisone/prednisolone (systemic glucocorticoid)
- Have known alcohol or other substance abuse disorder
- Are routinely taking medication-including, but not limited to, over-the-counter medications, supplements, medical marijuana or prescription pain medication-that is known to cause mental confusion or sedation or are using any of the medications
- Are routinely taking systemic glucocorticoids (example, prednisone, prednisolone, dexamethasone) at a dosage higher than the equivalent of prednisone 10 milligram (mg) daily
- Are currently using or have previously used chemotherapy for any cancer including mCRPC
- Are concurrently using any first-generation androgen-receptor blocker (example, bicalutamide, flutamide, nilutamide) for mCRPC
- Have previously taken enzalutamide or abiraterone acetate with prednisone
- Are not capable of completing tests using a computerized system or completing a participant survey
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Enzalutamide Group
Participants who are receiving enzalutamide in a clinical practice setting will be observed for tolerability and quality of life.
|
Participants who are receiving enzalutamide or abiraterone acetate in combination with prednisone in a clinical practice setting will be observed for tolerability and quality of life.
|
|
Abiraterone Acetate plus Prednisone group
Participants who are receiving abiraterone acetate in combination with prednisone in a clinical practice setting will be observed for tolerability and quality of life.
|
Participants who are receiving enzalutamide or abiraterone acetate in combination with prednisone in a clinical practice setting will be observed for tolerability and quality of life.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change From Baseline in Cogstate Tests at Month 2
Time Frame: Baseline and Month 2
|
The Cogstate computerized cognitive test battery will be used as the assessment tool in this study.
Overall, Cogstate measures a range of cognitive functions (example, psychomotor and memory function) using a number of different tests (example, choice reaction time, one-back memory).
This battery of tests was chosen because it has been shown to be sensitive to very small cognitive changes and has been tested in cancer participants after chemotherapy.
|
Baseline and Month 2
|
|
Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 at Month 2
Time Frame: Baseline and Month 2
|
The EORTC QLQ-C30 is a questionnaire developed to assess the quality of Life (QoL) of cancer participants.
The QLQ-C30 incorporates 9 multi-item scales: 5 functional scales (physical, role, cognitive, emotional, and social); 3 symptom scales (fatigue, pain, and nausea and vomiting); and a global health and QoL scale.
|
Baseline and Month 2
|
|
Change From Baseline in Functional Assessment of Chronic Illness Therapy Fatigue subscale (FACIT-Fatigue) at Month 2
Time Frame: Baseline and Month 2
|
The FACIT Measurement System is a collection of health-related QoL questionnaires targeted to the management of chronic illness.
The fatigue subscale (FACIT-Fatigue) is a validated, 13-item questionnaire that assesses fatigue in people being treated for a chronic illness.
|
Baseline and Month 2
|
|
Change From Baseline in Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog) at Month 2
Time Frame: Baseline and Month 2
|
The FACT-Cog is a validated, 37-item, subjective neuropsychological instrument designed to evaluate cancer participants perceived cognitive deterioration on their quality of life.
|
Baseline and Month 2
|
|
Participant or Caregiver Observational Questionnaire (Survey)
Time Frame: Baseline
|
If a participant has a regular caregiver, the participating physician will ask the caregiver to complete an optional observational, sponsor-developed questionnaire (survey) pertaining to his/her perception of the participants tolerability of treatment and QoL.
|
Baseline
|
|
Participant or Caregiver Observational Questionnaire (Survey)
Time Frame: Month 2
|
If a participant has a regular caregiver, the participating physician will ask the caregiver to complete an optional observational, sponsor-developed questionnaire (survey) pertaining to his/her perception of the participants tolerability of treatment and QoL.
|
Month 2
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants with Adverse Events (AEs) and Serious AEs
Time Frame: Screening up to follow-up (Approximately 2 Months)
|
An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
|
Screening up to follow-up (Approximately 2 Months)
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Janssen Scientific Affairs, LLC Clinical Trial, Janssen Scientific Affairs, LLC
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CR108103
- 212082PCR4038 (Other Identifier: Janssen Scientific Affairs, LLC)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.